Is Medibank Private stock a buy right now?
Medibank Private Limited (ASX: MPL) stands out as a steady performer within Australia's insurance and financial services sector. As of early May 2025, MPL is trading near its 52-week high at approximately $4.71 per share, with an average daily trading volume of just over 8 million shares. Investor interest has been robust, driven by strong half-year financial results: a 13.8% lift in underlying NPAT and double-digit profit growth across both its insurance and health services divisions. The market’s response remains constructive, with the stock posting a remarkable 32.7% gain over the past six months—a testament to sector resilience and effective management following the 2022 cyber incident. Notably, Medibank’s expansion in digital health and its growing Medibank Health segment have attracted positive attention. Technical indicators unanimously point to continued strength, as the recent golden cross pattern underlines fresh momentum. The consensus among more than 34 national and international banks sets the medium-term target price for MPL at $6.12, reflecting expectations that both dividends and earnings will continue to grow. While the sector faces regulatory and competitive headwinds, Medibank’s diversified business model and clear commitment to innovation position it favourably in the Australian market landscape.
- Market leader in Australian private health insurance, serving 3.7 million members.
- Consistent earnings growth with underlying NPAT up 13.8% in latest half-year.
- Healthy fully franked dividend yield of 3.65%, appealing to income-focused investors.
- Very low share price volatility (Beta 0.12), offering defensive portfolio qualities.
- Strong signals from all technical indicators support further upward share momentum.
- Ongoing cyber risk management and regulatory impacts from the 2022 data breach persist.
- Competition in health insurance may affect future customer acquisition and pricing power.
- What is Medibank Private?
- How much is Medibank Private stock?
- Our full analysis on Medibank Private </b>stock
- How to buy Medibank Private stock in Australia?
- Our 7 tips for buying Medibank Private stock
- The latest news about Medibank Private
- FAQ
Why trust HelloSafe?
At HelloSafe, our experts have been closely monitoring Medibank Private’s performance for more than three years. Each month, hundreds of thousands of Australians rely on us to break down market trends and highlight the best opportunities for investment. Please note, our analyses are intended for informational purposes only and do not represent investment advice. In line with our ethical charter, we have never been, and never will be, paid or influenced by Medibank Private.
What is Medibank Private?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australia | Medibank is a leading Australian provider in the private health insurance sector. |
| 💼 Market | ASX (Australian Securities Exchange), ticker: MPL | Listed on ASX, Medibank is widely accessible to Australian retail investors. |
| 🏛️ ISIN code | AU000000MPL3 | The ISIN uniquely identifies Medibank shares for domestic and global investors. |
| 👤 CEO | David Koczkar | Koczkar has led as CEO since May 2021, focusing on digital transformation and growth. |
| 🏢 Market cap | AUD $12.97 billion | Large market cap signals stability and strong sector position in Australia. |
| 📈 Revenue | AUD $4,085.7 million (HY25) | Steady premium revenue growth underpins profitability and market leadership. |
| 💹 EBITDA | Not disclosed directly | EBITDA not separately released; focus on operating profit and net profit metrics. |
| 📊 P/E Ratio (Price/Earnings) | 26.46 | High P/E suggests the stock is priced for growth, which may limit near-term upside. |
How much is Medibank Private stock?
The price of Medibank Private stock is rising this week. As of today, MPL shares are trading at AUD $4.71, marking a 1.07% gain over the past 24 hours and a notable 3.74% increase for the week. The company’s market capitalisation now stands at $12.97 billion, with a 3-month average trading volume of around 8.1 million shares. Medibank currently features a P/E ratio of 26.46, offers a dividend yield of 3.65%, and has a low beta of 0.12, indicating minimal volatility. This strong upward movement and defensive profile may appeal to Australian investors seeking steady performance in a dynamic market.
Check out the best brokers in Australia!Compare brokersOur full analysis on Medibank Private stock
Having thoroughly reviewed Medibank Private’s latest financial results in conjunction with its robust stock performance over the past three years, our analysis integrates proprietary algorithms with multi-source data—ranging from fundamental metrics to technical patterns, market sentiment, and comparative landscape. In this context, Medibank Private stands out as a compelling candidate among defensive Australian stocks, benefitting from sector resilience and internal transformation. So, why might Medibank Private stock once again become a strategic entry point into the Australian healthcare sector in 2025?
Recent Performance and Market Context
Medibank Private (ASX: MPL) has delivered a standout performance over the last twelve months, underscored by a share price increase of over 38%, outpacing sector and ASX benchmarks. Year-to-date in 2025, the stock has advanced an impressive 24.3%, with its current price at $4.71—remarkably close to its 52-week high of $4.75. This ascent is not just the result of positive macro tailwinds, but also consistent operational execution and sector-specific advantages.
The Australian private health insurance sector continues to exhibit defensive growth characteristics in a challenging macroeconomic backdrop. As households navigate higher cost-of-living pressures, the demand for health-related products and services remains resilient, reinforcing the case for Medibank’s core business. Moreover, the sector’s regulatory regime and demographic trends are structurally supportive: Australia’s ageing population, chronic disease burden, and a well-established private health system promote underlying policyholder growth.
- Solid half-year financial results in February 2025 painted a picture of strong revenue and profit growth
- Continued recovery post-cybersecurity incident
- Expansion of innovative digital healthcare services
- Medibank’s additional $160 million COVID-19 cash give-back, reinforcing customer-centricity
Combined, these market and company-specific factors have contributed to sustained investor interest and upward price momentum, positioning Medibank as one of the top-performing, large-cap healthcare insurers for Australian investors in 2025.
Technical Analysis
The technical landscape for Medibank Private is unequivocally bullish as of early May 2025, substantiated by a suite of indicators:
- Moving Averages: All major moving averages (5-, 20-, 50-, 100-, and 200-day) signal “Buy,” with the 50-day moving average having formed a classic “Golden Cross” above the 200-day MA—historically interpreted as an early signal for sustained uptrends.
- Oscillators:
- RSI (14): 66.8, suggesting strong momentum while not yet overbought—a sweet spot for ongoing accumulation.
- MACD: 0.033, in positive territory, highlighting bullish medium-term momentum.
- Stochastic Oscillator: 75.7, reinforcing a positive short-term bias with room before entering extreme overbought levels.
- CCI: 84.3, also indicating underlying price strength.
Key support levels at $4.65 and $4.60 have consistently held during recent minor pullbacks, providing a robust technical floor, while the $4.75 mark now stands as a new resistance threshold as the stock approaches record territory.
With sustained upward momentum and confirmation from both trend and oscillator indicators, the technical structure suggests Medibank Private may be entering a new bullish phase. Price consolidation above these support levels would not only mitigate downside risk but potentially set the stage for further breakout moves.
Fundamental Analysis
Medibank Private’s fundamentals reinforce the positive technical picture, notably through strong financial execution and prudent long-term strategy.
- Revenue & Profitability: The latest half-year results announced in February 2025 saw underlying NPAT climb by 13.8% to $298.7 million, group operating profit advance by 12.7%, and gains in key operating segments.
- Premium revenue grew 4.1% year-over-year to over $4 billion, indicating the company’s continued ability to attract and retain policyholders.
- Segment profit from Medibank Health soared by 40.8%, evidencing successful diversification beyond traditional insurance.
- Valuation: Medibank commands a P/E ratio of 26.5, aligned with growth-oriented, blue-chip defensive stocks within the ASX healthcare universe. With a price-to-book of 5.4, the valuation reflects premium attributes: category leadership, brand trust, and robust profitability.
- Dividend Profile: Investors benefit from stable, fully franked dividends—yielding an attractive 3.65%—and a consistently high payout ratio of 86%. This underlines both capital discipline and strong free cash flow conversion.
- Strategic Positioning:
- Category leadership: Medibank maintains the highest market share in Australian private health insurance, serving over 3.7 million customers.
- Brand strength: Its dual-brand strategy (Medibank and ahm)—alongside integrated digital wellness offerings—bolsters cross-selling and customer retention.
- Innovation: Recent investments in digital health (e.g., virtual care, telehealth, Amplar Health) position the company to capitalise on evolving health service modalities.
Medibank’s structural strengths—especially its innovation pipeline, entrenched market position, and disciplined capital management—justify renewed interest at present valuation levels.
Volume and Liquidity
Medibank Private’s strong trading volume, with a daily average of over 8 million shares, is emblematic of healthy investor engagement and institutional confidence. High liquidity ensures:
- Tight bid-ask spreads for efficient entry and exit
- Minimal slippage, even for larger or institutional trades
- Sustained share price discovery and valuation accuracy
The current float, given the stock’s size and spread of ownership, is favourable to dynamic pricing and responsive to positive news flow or fundamental catalysts. Persistent volume above long-term averages confirms that recent price advances are underpinned by broad market participation—not mere speculative flow.
Catalysts and Positive Outlook
Looking ahead, several bullish catalysts underpin a positive medium- and long-term outlook for Medibank Private:
- Product and Service Innovation: The expansion of virtual clinics and Amplar Health’s in-home and digital services broadens the company’s total addressable market and insulates profits from sector cyclicality.
- Strategic M&A: Management’s clear intent to deploy $150–250 million for targeted acquisitions by FY26 adds an optionality premium, with scope to accelerate EPS and diversify earnings streams.
- ESG and Corporate Stewardship: Continued investment in cybersecurity (post-2022 breach), a proactive ESG agenda, and industry-leading customer support have restored confidence among members, regulators, and stakeholders.
- Operational Efficiency: Commitment to $70 million in productivity savings within expense management supports margin expansion.
- Favourable Health Trends: Demographically, an ageing population and high demand for elective surgeries and wellness support position Medibank to maintain organic policyholder growth.
- Defensive Sector Attributes: The company continues to benefit from sector-wide tailwinds—stable regulatory regime, inelastic demand, and an environment where healthcare premiums have demonstrated resilience against cost-of-living pressure.
Moreover, health insurance regulation and government support create embedded floors beneath Medibank’s core business—a rare advantage in turbulent macro environments.
Investment Strategies
For investors seeking strategic entry into Australia’s healthcare and financial services sector, Medibank Private aligns with a range of portfolio objectives:
- Short-term: The convergence of all major technical buy signals, confirmation of new support at $4.65, and recent momentum enable tactical positioning for traders seeking near-term upside. Consolidation above $4.70 could prelude a sustainable test of new all-time highs, particularly ahead of Q2/FY25 updates or further M&A announcements.
- Medium-term: Those aiming for income plus capital appreciation will value the stock’s franked dividends, moderate volatility (Beta 0.12), and healthy growth profile. Structural improvements in margin and customer retention, combined with sector-wide resilience, deliver high visibility on earnings.
- Long-term: Investors focused on wealth preservation and compounding will appreciate Medibank’s defensive moat, essential nature of its service offering, and innovation-led expansion. Ongoing digital transformation, disciplined acquisition strategy, and customer-centric product development offer credible pathways to durable market leadership and robust returns.
Current levels appear to offer an attractive entry, either on mild pullbacks toward the $4.65–$4.70 range or as the stock positions for a fresh leg higher through $4.75 resistance.
Is it the Right Time to Buy Medibank Private?
In summary, Medibank Private combines robust financial health, sector leadership, and a proven capacity to deliver value for shareholders. The company’s resilience in the face of substantial operational setbacks (notably, the 2022 cyberattack), its renewed growth, and its successful shift toward innovative, high-margin health services underpin a compelling bullish narrative.
The convergence of strong near-term technical signals, a highly liquid and institutionally supported market, and credible management execution suggest the stock may be entering a new growth phase. Its attractive dividend, sector-defensive qualities, and strong balance sheet further set it apart as an appealing choice in today’s market.
While diligence is always required given persistent regulatory and competitive challenges, the risk/reward profile for Medibank Private seems to represent an excellent opportunity for investors seeking resilient exposure to the Australian healthcare ecosystem.
For those in pursuit of quality, stability, and moderate growth within the ASX, Medibank Private merits close and timely consideration—and may be poised to deliver outsized results as the market increasingly values defensive growth names in 2025.
How to buy Medibank Private stock in Australia?
Buying Medibank Private (ASX: MPL) stock online is a straightforward and secure process when using a regulated Australian broker. Investors have two main options: you can purchase Medibank Private shares outright (spot buying), making you a direct shareholder, or trade via Contracts for Difference (CFDs), which allows you to speculate on the share price without actually owning the shares. Spot buying is popular for long-term growth and dividends, while CFDs appeal to those seeking leverage and short-term trading opportunities. To help you choose the best platform, you’ll find a comparison of popular brokers further down this page.
Spot Buying
A cash, or spot purchase, means you’re buying Medibank Private shares in your own name on the Australian Securities Exchange (ASX). You become a part-owner and are eligible for dividends (including Medibank’s fully franked payouts) and potential capital gains. Brokers typically charge a flat commission per trade, often ranging from $5 to $15 AUD per order.
Example
Suppose Medibank Private’s share price is $4.71. With a $1,000 investment, and allowing for a $5 brokerage fee, you could buy approximately 211 shares ($1,000 - $5 = $995 ÷ $4.71 ≈ 211 shares).
Gain Scenario: If the share price rises by 10% to $5.18, your shares are now worth $1,100.
Result: +$100 gross gain, a +10% return on your investment (not including taxes or additional fees).
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Medibank Private’s price movements without owning the underlying shares. CFDs are leveraged instruments, so you can take larger positions with a smaller upfront investment. The main costs to consider are the “spread” (difference between buy and sell price) and overnight funding fees if you hold positions beyond a day.
Example
You open a CFD position with $1,000 and use 5x leverage, giving you market exposure of $5,000. If Medibank Private’s stock rises by 8%, your position increases 8% × 5 = 40%.
Result: +$400 gain on your $1,000 stake (excluding fees and potential losses if markets move against you).
Final Advice
Before investing, it’s essential to compare the fees, features, and regulatory safeguards of different brokers. Both spot buying and CFDs offer unique advantages that suit different investment strategies and risk appetites. Your choice should reflect your personal objectives, risk tolerance, and timeframe as an investor. Remember, a detailed broker comparison is available further down the page to help guide your decision.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Our 7 tips for buying Medibank Private stock
| 📊 Step | 📝 Specific tip for Medibank Private |
|---|---|
| Analyze the market | Review Medibank Private’s solid financials, sustained policyholder growth, and strong technical signals like the recent Golden Cross and consistent Buy indicators to assess current market momentum. |
| Choose the right trading platform | Select an established Australian broker that offers low ASX trading fees, access to Medibank Private (MPL), and support for franking credits to maximise dividend benefits. |
| Define your investment budget | Determine an amount that fits your risk profile, considering Medibank’s low beta (0.12), reliable dividends, and defensive sector profile while keeping your portfolio balanced. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Medibank’s consistent dividend yield, fully franked payouts, and strategic growth in health services and technology. |
| Monitor news and financial results | Stay alert to Medibank Private’s half-year and full-year results, changes in dividend policy, and ongoing developments like cybersecurity updates and M&A activities. |
| Use risk management tools | Utilise features like stop-loss orders and regular portfolio reviews, particularly given potential sector changes and Medibank’s regulatory environment. |
| Sell at the right time | Plan exits around key technical resistance levels, especially near 52-week highs, or ahead of events that may introduce volatility, such as regulatory reviews or earnings announcements. |
The latest news about Medibank Private
Medibank Private shares have reached a new 52-week high, highlighting robust investor confidence. Over the past week, MPL.AX rose 3.74% to AUD $4.71, capping a remarkable 6-month advance of 32.68%. This upward trend is reinforced by unusually strong daily trading volumes, positive market sentiment, and solid technical indicators signalling ‘Buy’ across all major moving averages, as well as a “golden cross” pattern, often regarded as a bullish market signal for sustained price gains.
Financial results released in late February reaffirmed Medibank’s ongoing profit growth and operational resilience. The company reported a 13.8% jump in underlying Net Profit After Tax (NPAT) to $298.7 million for HY25, driven by premium revenue growth (+4.1%) and expanding profits in both the core health insurance and health services divisions. Notably, the Medibank Health segment saw segment profit soar by 40.8%, with management signalling continued focus on digital services and operational efficiencies.
Dividend stability and tax effectiveness remain standout features for Australian investors. Medibank’s latest interim dividend was announced at 7.8 cents per share, fully franked, with a forward yield of 3.65%. This reliable payout, together with low share price volatility (beta of 0.12) and 100% franking, continues to make MPL shares especially attractive for income-seeking Australian residents and superannuation funds who benefit from favourable tax treatment on franked dividends.
Strategic innovation and expansion initiatives are boosting future growth prospects and corporate reputation. Recent investments include the launch of a virtual psychology clinic, expansion of the Amplar Health division, and the opening of a short-stay, no-gap surgical centre in Melbourne. These measures have not only enhanced Medibank’s value proposition in the local healthcare market but also support its target to grow market share in line with or above industry averages during the second half of FY25.
Customer advocacy and operational recovery after the 2022 cyberattack have returned to pre-breach levels, restoring stakeholder confidence. Following a significant investment of AU$126 million in security improvements, Medibank’s resilience is reflected in regained customer trust and business momentum. The company now reports that customer advocacy metrics, premium growth, and policyholder volumes have strengthened, indicating effective management of prior challenges and reducing perceived long-term reputational risk.
FAQ
What is the latest dividend for Medibank Private stock?
Medibank Private currently pays a fully franked dividend. The latest interim dividend was AUD $0.078 per share, announced on February 27, 2025, with an ex-dividend date of March 6, 2025. The annualized dividend amounts to $0.172 per share, equating to a yield of 3.65%. Medibank has a strong track record of paying dividends, consistently maintaining a high payout ratio, which appeals to income-focused investors in Australia.
What is the forecast for Medibank Private stock in 2025, 2026, and 2027?
Based on the current share price of $4.71, the projected values are: end of 2025 - $6.12, end of 2026 - $7.07, and end of 2027 - $9.42. These forecasts reflect optimism around Medibank’s robust financial performance, expanding digital capabilities, and the company’s leadership in the Australian health insurance sector. Ongoing innovation and planned investments further support expectations for solid long-term growth.
Should I sell my Medibank Private shares?
Holding onto Medibank Private shares may be appropriate for many investors given the company’s strong fundamentals and low volatility profile. Medibank remains Australia’s largest private health insurer, with consistent profitability, a resilient business model, and steady dividend payments. The stock’s upward price momentum and sector stability point to ongoing potential for value appreciation, particularly for those with a mid- to long-term investment horizon.
How are dividends from Medibank Private stock taxed in Australia?
Dividends paid by Medibank Private are fully franked, meaning investors receive a franking credit to offset their Australian tax liability, reducing overall tax on dividend income. For most resident investors, this can substantially lower or even eliminate tax owed on these dividends. Capital gains from selling Medibank shares may also be eligible for the 50% discount if the shares are held for at least 12 months.
What is the latest dividend for Medibank Private stock?
Medibank Private currently pays a fully franked dividend. The latest interim dividend was AUD $0.078 per share, announced on February 27, 2025, with an ex-dividend date of March 6, 2025. The annualized dividend amounts to $0.172 per share, equating to a yield of 3.65%. Medibank has a strong track record of paying dividends, consistently maintaining a high payout ratio, which appeals to income-focused investors in Australia.
What is the forecast for Medibank Private stock in 2025, 2026, and 2027?
Based on the current share price of $4.71, the projected values are: end of 2025 - $6.12, end of 2026 - $7.07, and end of 2027 - $9.42. These forecasts reflect optimism around Medibank’s robust financial performance, expanding digital capabilities, and the company’s leadership in the Australian health insurance sector. Ongoing innovation and planned investments further support expectations for solid long-term growth.
Should I sell my Medibank Private shares?
Holding onto Medibank Private shares may be appropriate for many investors given the company’s strong fundamentals and low volatility profile. Medibank remains Australia’s largest private health insurer, with consistent profitability, a resilient business model, and steady dividend payments. The stock’s upward price momentum and sector stability point to ongoing potential for value appreciation, particularly for those with a mid- to long-term investment horizon.
How are dividends from Medibank Private stock taxed in Australia?
Dividends paid by Medibank Private are fully franked, meaning investors receive a franking credit to offset their Australian tax liability, reducing overall tax on dividend income. For most resident investors, this can substantially lower or even eliminate tax owed on these dividends. Capital gains from selling Medibank shares may also be eligible for the 50% discount if the shares are held for at least 12 months.
